Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics
November 18 2021 - 7:05AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced it will host an inaugural Innovation Day by live webcast
on December 13. The event will include presentations of the
company’s innovation pipeline by members of Stereotaxis leadership
with a live Q&A session.
What: |
|
Stereotaxis Innovation Day –
Pioneering Endovascular Robotics |
When: |
|
Monday, December 13, 2021 at 4:00
p.m. EST (1:00 p.m. PST) |
Registration: |
|
Please register in advance by
visiting www.stereotaxis.com/innovation-day |
“We are excited to share Stereotaxis’ next wave
of innovations and the transformative impact these innovations will
have on the advancement of endovascular surgery,” said David
Fischel, Chairman and CEO of Stereotaxis.
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L. FischelChairman
and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2024 to May 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From May 2023 to May 2024